Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or lactating are ineligible
Females who are breastfeeding or pregnant at screening or baseline (as documented by a positive beta-human chorionic gonadotropin [beta-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 IU/L or equivalent units of beta-hCG [or hCG]); a separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
Pregnant or nursing (lactating) women, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 10 mIU/mL); pregnancy is ruled out by a beta hCG test completed if necessary with an ultrasound
Women of childbearing potential who currently are pregnant (human chorionic gonadotropin positive [HCG+]) or who are not practicing adequate contraception
Females who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or breast-feeding
Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin [B-hCG] pregnancy test)
DONOR: females who are pregnant (positive serum beta-human chorionic gonadotropin [B-HCG]) or uninterruptible breastfeeding
Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test) at screening or pre-dose on day 1
Performed within 10 business days of treatment initiation with the exception of beta-human chorionic gonadotropin (HCG) (72 hours), if applicable: Absolute neutrophil count (ANC) >= 1000 /uL.
Pregnant or breastfeeding women who do not consent to stop breast-feeding while on study treatment and for 30 days after the use of the investigational vaccine where pregnancy is confirmed by a positive, rising human chorionic gonadotropin (hCG) laboratory test
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause
Female patients who are pregnant confirmed by beta human chorionic gonadotropin (bHCG) laboratory (lab) test
Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test)
Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or breast feeding
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause; [women are considered postmenopausal if they are >= 12 months without menses, in the absence of endocrine or anti-endocrine therapies]
Normal beta-human chorionic gonadotropin (HCG) (per the local laboratory assay) within 14 days of RPLND
Subject is pregnant or nursing; serum or urine beta-human chorionic gonadotropin (HCG) must be checked in all non-postmenopausal patients or patients of childbearing potential
WOCBP who have a positive beta-human chorionic gonadotropin (hCG) test or are breastfeeding
Female patients who are diagnosed as pregnant by beta human chorionic gonadotropin (hCG) testing (per institutional practice) or breast-feeding
Female patients who are pregnant (positive beta-human chorionic gonadotropin [B-HCG]) or breastfeeding
Pregnant or nursing (to be confirmed with quantitative human chorionic gonadotropin [HCG] testing)
Negative beta-human chorionic gonadotropin (hCG) pregnancy test within 2 weeks before enrollment for premenopausal women of reproductive capacity and for women less than 12 months after menopause; pregnancy screening will be conducted for women up to the age of 50 years per institutional standard
Pregnant or need to breast feed during the study period (negative beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for 31 weeks after the last dose of nivolumab
DONOR:\r\n* Donors will be excluded if they are an identical twin of the recipient\r\n* Females who are pregnant (positive serum beta human chorionic gonadotropin beta [? HCG]) or uninterruptible breastfeeding\r\n* HIV seropositive\r\n* Donors receiving experimental therapy or investigational agents unless approved by the protocol chair
Negative serum beta-human chorionic gonadotropin (HCG)
Women of childbearing potential who currently are pregnant (beta-human chorionic gonadotropin [HCG]+) or who are not practicing adequate contraception
Pregnant or lactating females; women of non-childbearing potential is defined as women who are postmenopausal (no menses for > one year) or who have had a hysterectomy and will not require beta-human chorionic gonadotropin (B-hCG) testing
Women who are pregnant (determined by high titer of serum beta-human chorionic gonadotropin [HCG]) or breast-feeding; (women with reproductive potential must practice adequate contraception)
Pregnant or nursing women; women of child-bearing age must be tested for urinary or plasma beta-human chorionic gonadotropin (hCG)
Women of childbearing potential who currently are pregnant (beta-Human chorionic gonadotropin positive [HCG+]) or who are not practicing adequate contraception
Subject is pregnant, has a positive serum human chorionic gonadotropin (hCG) or is lactating
Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or are lactating
Beta human chorionic gonadotropin (beta HCG) negative
Female patients who are pregnant (positive beta-human chorionic gonadotropin [b-HCG]) or breast feeding.
Pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-human chorionic gonadotropin (hCG) laboratory test; breast-feeding should be discontinued
Women who are pregnant or breast-feeding; women of reproductive potential must have a negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy test obtained within 7 days before the start of study treatment
Women of childbearing potential who currently are pregnant (beta-human chorionic gonadotropin [HCG]+) or who are not practicing adequate contraception or who are breastfeeding
Negative ?-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause. [Women are considered postmenopausal if they are ?12 months without menses, in the absence of endocrine or anti-endocrine therapies.]
Women of childbearing potential with a positive serum beta human chorionic gonadotropin (hCG)
Female patients who are pregnant (positive b-human chorionic gonadotropin [HCG]) or breastfeeding
Female patients who are pregnant (positive beta-human chorionic gonadotropin [HCG]) or breastfeeding will be excluded from study entry; sexually active men and women must use contraceptive techniques during and for 4 weeks following completion of maintenance therapy
The patient is pregnant (confirmed by serum beta human chorionic gonadotropin [b-HCG], if applicable) or is breastfeeding
Negative serum human chorionic gonadotrophin (HCG) pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after menopause
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause
Patients will be excluded if they are pregnant as assessed by serum beta human chorionic gonadotropin (b-HCG); a serum b-HCG test will be performed no greater than 14 days prior to study registration for women of childbearing potential
Pregnant (i.e., positive beta-human chorionic gonadotropin test) or lactating
Is pregnant (confirmed by beta human chorionic gonadotrophin [?-HCG]) or lactating.
Patient is pregnant (confirmed by serum beta- b-human chorionic gonadotropin [HCG] if applicable) or is breastfeeding
HAPLO-IDENTICAL DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study
DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [b-HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study
Pregnant women with a positive (blood beta-human chorionic gonadotropin [B-HCG]) pregnancy test are excluded from this study
Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive [HCG+]) or breast feeding
Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be obtained from women of childbearing potential; fertile men and women should use effective contraception
Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive [b-HCG+]) or breast feeding
Pregnancy: women of childbearing potential who are beta(B)-human chorionic gonadotropin (HCG) positive (+)
Pregnant or breast feeding women; positive pregnancy test (serum or urine beta-human chorionic gonadotropin [HCG]) for women of reproductive potential
Women of childbearing potential who are lactating, pregnant or there is the likelihood of becoming pregnant within the coming 12 months; a positive serum beta-human chorionic gonadotropin test at time of screening for entry into study
Pregnant females as determined by positive human chorionic gonadotropin (hCG) test at screening or prior to dosing.
Female subjects must not be pregnant as documented by a negative beta-human chorionic gonadotropin (beta-hCG) test with a minimum sensitivity 25 IU/L or equivalent unit of beta-hCG at Screening and Baseline, or breastfeeding.
Pregnancy (positive serum beta human chorionic gonadotropin [b-HCG]) or breastfeeding
Pregnant or breast-feeding; pre-menopausal patients must have a negative serum human chorionic gonadotropin (HCG) within 14 days of enrollment
Pregnant (i.e., positive beta-human chorionic gonadotropin [HCG]) or breast feeding
Pregnant or need to breast feed during the study period (negative urine beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for 1 month after the last dose of AED
Women who are pregnant; patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator, pregnancy testing is not required per protocol to determine study eligibility
Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery
Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery
Female patient who is pregnant or lactating (the possibility of pregnancy has to be excluded by negative serum or urine beta-human chorionic gonadotropin [?-HCG] results, obtained within 24 hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)
Any woman who is pregnant or has reason to believe she is pregnant or any woman who is lactating (the possibility of pregnancy has to be excluded by negative urine beta-human chorionic gonadotropin [beta-HCG] results, obtained within 24 hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)
Women who are pregnant (confirmed by serum beta [b]-human chorionic gonadotropin [HCG] in women of reproductive age) or breast feeding
Pregnant women and women who are breast feeding will be excluded from this study; (the Vanderbilt University Medical Center radiology “MRI Procedure Screening Form” will be used to identify and exclude subjects who are pregnant or breastfeeding; a urine pregnancy test/or serum beta human chorionic gonadotropin [HCG] will also be performed for each pre-menopausal subject)
Pregnant (confirmed by serum beta human chorionic gonadotropin [b-HCG] in women of reproductive age) or breast feeding
The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding
The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding
